Although conventional anti-VEGF therapy has achieved favorable results in controlling RVO-associated macular edema, it still leaves a therapeutic gap in addressing Ang-2–mediated vascular instability and chronic inflammation. This evidence concerns the gene VEGFA and macular retinal edema.